Actylis and Novo Nordisk Pharmatech are expanding their strategic partnership for the distribution of Benzalkonium Chloride in targeted European countries.
Join us at the most important conferences in 2025. Our teams of experts will be there to answer all your questions, especially about our Recombinant Insulin and TrypsiNNex®. We will exhibit at: Biologics Manufacturing Asia at Marina Bay Sands Expo & Convention Centre in Singapore, March 12-13, 2025 World Vaccine
TrypsiNNex® insights Achieve consistent, reproducible bioprocessing with TrypsiNNex® Resources Consistency and reproducibility are essential for success in highly regulated pharmaceutical manufacturing. TrypsiNNex® is designed to deliver reliable processes and predictable outcomes – batch after batch. Why choose TrypsiNNex®? TrypsiNNex® is a recombinant trypsin expressed in E. coli and manufactured using a
TrypsiNNex® posters & infographics Take control of common biomanufacturing challenges with TrypsiNNex® TrypsiNNex® Discover how TrypsiNNex® can improve your upstream cell-based vaccine or drug production. TrypsiNNex® is completely animal-free, helping to reduce costs associated with virus testing while delivering consistently high β-trypsin content well above minimum specifications of 70%. Download
Ulla Grove Krogsgaard Thomsen holds a M.Sc. in Pharmaceutical Sciences from 1992 and a Ph.D. in Structural and Analytical chemistry from 1996, both obtained at University of Copenhagen. Dr. Thomsen joined Novo Nordisk Pharmatech A/S in 2021 as the CEO. Since 2019 she has been a member of the Bord
Unlocking the potential of antimicrobial preservation and HPLC method validation for Benzalkonium Chloride Are you seeking the perfect equilibrium between antimicrobial preservation and patient safety? Do you require expert assistance in validating your HPLC method for recovering Benzalkonium Chloride in a finished formulation? Look no further. In our groundbreaking technical
Christian Brøgger Stolberg holds a Master of Science (MSc) in Medicine with Industrial Specialisation / Biomedicine. Mr Stolberg joined Novo Nordisk Pharmatech in 2017 as a QA professional. In 2021 he joined production support as process responsible for the enzymes purification process in F8/F11. Mr Stolberg joined the KNSF in
Joachim Hagemeister joined Novo Nordisk Pharmatech A/S in 2012 as an operator specialised in clean room and aseptic production. Since 2016 he has been a member of the Bord of Directors. Mr. Hagemeister joined Novo Nordisk A/S in 2001 and has been working with Glucagon in Gentofte, inspection of penfill
Københavnsvej 216
4600 Køge,
Denmark
+45 5667 1000
[email protected]
CVR-no. 13246149
